The preclinical data is a positive catalyst for GLIX1's pipeline diversification, but clinical validation is still pending. Watch for Phase 1/2a updates in H2 2026 and potential partnership interest. The low market cap ($14M) may amplify price moves on binary clinical events.
Price Chart
Executive Summary
BioLineRx announced positive preclinical data demonstrating strong synergy between its lead candidate GLIX1 and PARP inhibitor olaparib in a patient-derived ovarian cancer xenograft model. The combination at low doses showed substantially better efficacy than monotherapy and comparable efficacy to cisplatin, reinforcing the synthetic lethality mechanism. The company plans to add an ovarian cancer arm to the ongoing Phase 1/2a study, expanding GLIX1's potential addressable market.
Key Facts
- GLIX1 + olaparib combination at low doses showed substantially better efficacy than control and monotherapy arms in a PDX ovarian cancer model.
- Combination tumor reduction was comparable to cisplatin, the current chemotherapy benchmark.
- Data reinforces synthetic lethality between GLIX1 and PARP inhibitors, potentially broadening PARPi use in HR-proficient ovarian cancer.
- BioLineRx plans to include an ovarian cancer arm in the expansion part of the ongoing Phase 1/2a study of GLIX1.
- Phase 1/2a dose escalation for GLIX1 in glioblastoma is ongoing; updates expected H2 2026, full results in 2027.
Financial Impact
No immediate financial impact; preclinical data de-risks pipeline expansion but does not affect current revenue or cash position.
Risk Factors
- Preclinical efficacy may not translate to clinical outcomes in humans.
- Company has limited cash runway and may require future dilutive financing.
- Competition in ovarian cancer from approved PARP inhibitors and other combination therapies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003438 |
| Document: zk2635661.htm | 0001178913-26-003438 |
| Document: 0001178913-26-003438-index-headers.html | 0001178913-26-003438 |
| Document: 0001178913-26-003438-index.html | 0001178913-26-003438 |
| Document: 0001178913-26-003438.txt | 0001178913-26-003438 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 6-K | $2.04 | awaiting T+20 | — | $2.01 (−1.47%) |
Oct 5, 2026 22d ago | EFFECT | $2.32 | awaiting T+20 | — | $2.01 (+13.36%) |
Sep 25, 2026 4w ago | F-1 | $2.43 $2.00 | ▼ −17.70% | ▼ −17.66% | $2.01 (−17.28%) |
Sep 10, 2026 6w ago | 6-K | $2.57 $2.21 | ▼ −13.99% | ▼ −16.12% | $2.01 (−21.77%) |
Aug 31, 2026 8w ago | 424B5 | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 31, 2026 8w ago | 6-K | $2.80 $2.36 | ▲ +15.71% | ▲ +15.34% | $2.01 (+28.21%) |
Aug 28, 2026 8w ago | 6-K | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Aug 28, 2026 8w ago | Press Release | $2.60 $2.43 | ▲ +6.54% | ▲ +6.80% | $2.01 (+22.69%) |
Jul 8, 2026 15w ago | 6-K | $3.01 $2.72 | ▼ −9.73% | ▼ −13.01% | $2.01 (−33.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers